Sep 24, 2024
Japan's Ministry of Health, Labour and Welfare Approves PADCEV(TM) (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
Sep 05, 2024
Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
Jul 22, 2024
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy
Jun 10, 2024
Astellas Coordinates Patient Advocacy Organization (PAO) Action Week(TM) to Connect Patients with Critical Resources
May 30, 2024
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
May 08, 2024
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
Mar 28, 2024
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Mar 22, 2024
Astellas Receives Positive CHMP Opinion for XTANDI(TM) in Additional Recurrent Early Prostate Cancer Treatment Setting
Mar 03, 2024
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
Feb 15, 2024
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
Feb 15, 2024
PADCEV(TM) (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
Feb 06, 2024
Astellas Makes Announcement about Management Structure
Feb 01, 2024
Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl